Skip to main content
Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
68.14
+0.77 (1.14%)
At close: Mar 9, 2026, 4:00 PM EDT
68.25
+0.11 (0.16%)
After-hours: Mar 9, 2026, 7:51 PM EDT

Halozyme Therapeutics Revenue

In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth. Halozyme Therapeutics had revenue of $451.77M in the quarter ending December 31, 2025, with 51.60% growth.

Revenue (ttm)
$1.40B
Revenue Growth
+37.55%
P/S Ratio
5.76
Revenue / Employee
$3,301,681
Employees
423
Market Cap
8.04B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.40B381.29M37.55%
Dec 31, 20241.02B186.07M22.44%
Dec 31, 2023829.25M169.14M25.62%
Dec 31, 2022660.12M216.81M48.91%
Dec 31, 2021443.31M175.72M65.67%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Bio-Techne 1.22B
Arrowhead Pharmaceuticals 1.09B
Axsome Therapeutics 638.50M
Krystal Biotech 389.13M
ImmunityBio 113.29M
Cytokinetics 88.04M
Praxis Precision Medicines 7.46M
ABIVAX Société Anonyme 6.23M
Revenue Rankings

HALO News

More News